At-Home RSV Test for Children: FDA Clears Flowflex Plus 4-in-1 for Ages 6 Months and Up

An at-home RSV test is available for the first time after the FDA cleared ACON’s Flowflex Plus 4-in-1 panel, which also detects influenza A, influenza B, and COVID-19 with a single nasal swab. The clearance covers infants as young as 6 months when an adult uses the supplied swab guard.

January 24, 2026 · 4 min read

The Story at a Glance:

An at-home RSV test cleared for use in infants is now on the US market: ACON’s Flowflex Plus 4-in-1 panel covers RSV, flu A, flu B, and COVID-19 in a single nasal swab.
Use is age-tiered: self-test from 14 years, adult-administered for ages 2–13, and adult-administered with a swab guard for infants 6–23 months.
Reported positive percent agreement against RT-PCR ranges from 91.6% (COVID-19) to 94.1% (RSV); negative percent agreement is 99.8% or better for every analyte.
The test is a triage tool, not a substitute for clinical evaluation — the labeling specifically directs caregivers of infants to contact a clinician regardless of the result.

What Happened

The FDA granted 510(k) clearance to ACON Laboratories’ Flowflex Plus RSV + Flu A/B + COVID Home Test (K251749), the first at-home RSV test cleared for non-prescription use in the United States. ACON announced retail availability on January 23, 2026, with distribution at CVS, Walgreens, Albertsons, and other national pharmacy and grocery chains.

The lateral-flow rapid antigen panel uses a single anterior nares swab and reports results in 15 minutes for four respiratory pathogens: respiratory syncytial virus (RSV), influenza A, influenza B, and SARS-CoV-2. Use is tiered by age. Adolescents 14 and older may self-test. For children 2 through 13, an adult administers the swab. For infants 6 to 23 months, an adult collects the sample using ACON’s proprietary swab guard, which the company developed to limit how far the swab advances into the nares.

The 510(k) pathway is a higher regulatory bar than the Emergency Use Authorization (EUA) route through which several earlier respiratory antigen home tests reached the market.

Why an At-Home RSV Test Matters

RSV is the leading cause of hospitalization among US infants, accounting for an estimated 58,000 to 80,000 admissions in children younger than 5 each year, according to American Academy of Pediatrics (AAP) figures. Until now, RSV testing required a clinic, urgent care, or emergency department visit — a friction point for families weighing whether a febrile or wheezy infant warranted in-person evaluation.

An at-home RSV test offers earlier triage information when an infant develops fever, cough, congestion, or wheezing during respiratory virus season. Distinguishing RSV from influenza has direct management implications: oseltamivir is indicated for influenza, while RSV management in outpatients is largely supportive with red-flag monitoring. Identifying COVID-19 also remains relevant for treatment eligibility in higher-risk children and for isolation decisions in households with vulnerable contacts.

At-Home RSV Test Performance: Key Numbers

The 510(k) submission compared the Flowflex Plus to FDA-cleared, highly sensitive RT-PCR molecular assays. Performance versus the molecular reference, as reported by ACON:

RSV: Positive percent agreement (PPA) 94.1%; negative percent agreement (NPA) 99.8%
Influenza A: PPA 92.9%; NPA 99.8%
Influenza B: PPA 92.9%; NPA 99.9%
SARS-CoV-2: PPA 91.6%; NPA 99.9%

Several practical limitations matter for pediatric use. Recent intranasal FluMist administration may produce false-positive influenza A or B results at certain dilutions, per the package insert. Antigen test sensitivity scales with viral load, so very early (presymptomatic) and very late (recovering) testing can underestimate infection. A negative result does not rule out coinfection with another pathogen. The instructions for use direct caregivers of children 6 to 23 months to contact a healthcare provider regardless of result if symptoms persist or worsen.

What to Counsel Families On

Pediatric infectious disease practice has long held that a positive antigen test does not replace clinical evaluation in young children. The new at-home option compresses the diagnostic timeline but does not change the triage logic: red flags such as apnea, retractions, poor feeding, cyanosis, or dehydration still warrant in-person assessment regardless of the result on the cassette.

“This test gives people clarity sooner, and in the comfort of their own home.” — Michael Lynch, VP of Sales and Marketing, ACON Laboratories (industry)

The 2025 AAP RSV policy statement frames prevention — nirsevimab, clesrovimab, or maternal RSVpreF vaccination — as the principal strategy for infants in their first season. Home testing addresses a downstream triage question, not a substitute for immunization or pediatrician evaluation.

What’s Next

Real-world performance data in young infants — where viral shedding kinetics and swab technique differ from older children — will be important to monitor through post-market surveillance. Any signals on false-positive rates after FluMist exposure or false-negative rates during low-prevalence months will likely shape future clinical guidance. Comparator multipathogen home tests previously authorized under EUA may now seek formal 510(k) clearance using the Flowflex precedent.

Bottom Line

Counsel families that an at-home RSV test does not replace examination of a febrile or wheezing infant — direct caregivers of children under 2 to call regardless of the cassette result.
Frame a positive home test as confirming the pathogen, not the disposition: red flags (apnea, retractions, poor feeding, cyanosis, dehydration) still drive triage decisions.
Ask about recent FluMist administration when interpreting positive influenza results from any home antigen test.
Reinforce RSV prevention with nirsevimab, clesrovimab, or maternal RSVpreF vaccination per AAP guidance — testing sits downstream of immunization, not in place of it.

Sources

ACON Laboratories. Flowflex Launches First FDA-Cleared 4-in-1 Home Test Detecting RSV, Flu A/B and COVID for Ages 6 Months+. Press release, January 23, 2026. ACON Laboratories Press Release on Flowflex Plus 4-in-1 Launch
ACON Laboratories. Flowflex Plus RSV + Flu A/B + COVID Home Test — Instructions for Use (510(k) K251749). 2026. Flowflex Plus 4-in-1 Instructions for Use (PDF)
Contemporary Pediatrics. FDA clears first at-home test to detect RSV, influenza, and COVID-19 in infants as young as 6 months. January 23, 2026. Contemporary Pediatrics — Coverage of Flowflex Plus Pediatric Clearance
Contagion Live. FDA Clears First At-Home Diagnostic for RSV, Influenza, and COVID-19 in Adults, Young Infants. January 2026. Contagion Live — At-Home RSV/Flu/COVID Diagnostic Clearance
American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for the Prevention of RSV Disease in Infants and Children: Policy Statement. Pediatrics, November 2025;156(5):e2025073923. AAP 2025 Policy Statement on RSV Prevention
Centers for Disease Control and Prevention. RSV Immunization Guidance for Infants and Young Children. 2025. CDC RSV Immunization Guidance for Infants and Young Children